Biochemical Mechanisms Mediating the Immunomodulatory and Anti-Atopic Dermatitis Effects of GammaQ in a DNCB-Induced BALB/c Mouse Model

Sang Park and Victor Zammit

Background and Objective: Individual components, such as gamma-linolenic acid, quercetin and bromelain, yield positive effects on immune regulation and atopic dermatitis (AD). Despite this, the collective influence and clinical effectiveness of GammaQ, a composite containing gamma-linolenic acid, quercetin and bromelain, in modulating immunity and preventing AD is still unclear. Thus, this study aimed to assess the clinical efficacy and immunomodulatory mechanisms of GammaQ using a DNCB-induced atopic dermatitis mouse model. Materials and Methods: A total of 30-day dietary interventions with 0, 2.0, 3.5 and 5.0% GammaQ were administered, after which biochemical markers, skin lesion scores, histopathological changes and gene expression profiles were assessed in DNCB-induced atopic dermatitis model mice. Data were analyzed using SAS (2023), with results expressed as mean±SE; group differences were assessed by ANOVA followed by Duncan’s multiple range test at p<0.05 (95% confidence level). Results: The group receiving 5.0% GammaQ (providing daily: Gamma-linolenic acid 3.15 mg/day, quercetin 0.43 mg/day and bromelain 0.72 mg/day) exhibited significant reductions in both histamine and IgE concentrations, with improved clinical and histopathological features of the skin, as well as substantial downregulation of genes associated with atopic dermatitis compared to the other groups (p<0.05). Conclusion: These results indicate that GammaQ may serve as a natural bioactive agent for enhancing immune function and mitigating atopic dermatitis symptoms in both humans and companion animals.

View Fulltext Back